Background
Thrombophilia refers to an abnormality of blood coagulation that increases the risk of thrombosis. Abnormalities of any component of Virchow’s triad (circulatory stasis, vascular wall injury or hypercoagulable state) can lead to thrombosis. Most heritable thrombophilias are heterozygous defects. Hereditary thrombophilia arise as a result of over-activity of coagulation factors. The aim of this study was to perform a screening of pregnant women hospitalized in our hospital for hereditary thrombophilia. 
Material and methods
Our study group included 819 pregnant women. Genetic tests for specific mutations included methylenetetrahydrofolate reductase (MTHFR) gene mutation, factor V Leiden mutation, prothrombin 20210 and factor XIII mutation. 
Results 
The incidence of high-risk inherited thrombophilias is low in our study, so  the frequency of homozygous factor V Leiden mutation (n=2) is equal with the incidence of homozygous prothrombin G20210A (n=2) mutation- 0.24%.  The incidence of heterozygous factor V Leiden was 17,09 % (n=140) , heterozygous prothrombin G20210A mutation was 3.29% (n=27)  , homozygosity for the C677T polymorphism of  methylene tetrahydrofolate reductase mutations was 5% (n=41) , homozygosity for the A1298C polymorphism is present in 3.17% (n=26) of pregnant women included in our study. Also heterozygous  methylene tetrahydrofolate reductase mutations (C677T, A1298C) were present at  48.35%.
Conclusions
Hereditary thrombophilia is a genetic condition of heterogeneous etiology, determined by genetic mutations that have been found in all factors of coagulation. There is no curative treatment for genetic thrombophilia.Pregnant women  that presented risk factors for thrombosis and were diagnosed with high risk hereditary thrombophilia received prophylactic anticoagulant treatment.

COGI-2018